Company’s specialty ramp-up is progressing well. Expect profit contribution from specialty to rise sharply in the next 2-3 years and FY21 annual report reiterates commitment to this segment.
There was a sharp decline in SG&A for global specialty business but some costs may return, CLSA added.
Sun Pharmaceutical Industries was quoting at Rs 787.90, up Rs 3.95, or 0.50 percent on the BSE.
News source:- Moneycontrol